Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)

NCT01552408 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: 0.3 mg ranibizumab
PROCEDURE: Targeted Pan Retinal Photocoagulation

Sponsor

David M. Brown, M.D.

Collaborators

[object Object]